Purpose: The present study examined the clinicopathological impact of survivin expression in oesophageal squamous cell carcinoma (ESCC). In addition, the biological role of anti-apoptosis parameter in ESCC was examined immunohistochemically. Patients and method: Subjects comprised 71 patients followed up for 5 years after surgery for ESCC and analysed immunohistochemically to examine the clinicopathological impact of survivin expression. Separately, 37 fresh frozen samples of ESCC obtained recently were examined concerning splicing variant expression of survivin using reverse-transcription polymerase chain reaction (RT-PCR). Results: Immunohistochemical survivin expression was detected in the nuclei of 10 ESCC specimens (14.1%) and cytoplasm of 22 specimens (31.0%). Nuclear expression displayed no clinicopathological implications, but cytoplasmic expression correlated with histological differentiation ( p = 0.002) and tumour invasion ( p = 0.073) and showed prognostic impacts in univariate ( p = 0.0184) and multivariate ( p = 0.0299) analyses. Survivin, survivin-2B and survivin-deltaEx3 mRNA were amplified in 31 (83.8%), 23 (62.2%) and 26 (70.3%) specimens, respectively, by RT-PCR. Survivin-2B level related significantly with histological differentiation ( p = 0.038), but no other significant implication was identified between any mRNA and clinicopathological factors. Conclusion: As a molecular biological anti-apoptotic factor, survivin expression was of use in assessing prognosis in ESCC. Inhibition of survivin may be useful as a molecular biological therapy in ESCC. #
Introduction
Experimental and clinical trials using molecular biological targets in cancer therapy have increasingly been reported. Hundreds of molecular biological factors have been reported and several have been applied clinically.
Apoptosis is one of the critical parameters reflecting the biological behaviour of cancers and suppression of apoptosis is known to play a crucial role in carcinogenesis and cancer progression.
Survivin maps to chromosome 17q25, and was initially reported by Ambrosini as a gene playing a role as an apoptosis inhibitor, with expression detectable in various cancers and normal foetal tissues, but not in adult human normal tissues [1] . Survivin expression has been reported to indicate unfavourable clinical outcomes in patients with various cancers, including colorectal, lung and breast cancers [2, 3] . Mahotka isolated two novel splice variants, survivin-deltaEx3 and survivin-2B in 1999, and we have subsequently demonstrated that splice-form 2B indicates gastric cancer progression [4, 5] . In addition, survivin-2B retains a part of intron 2 as a cryptic exon and is localised in the cytoplasm similar to survivin and has a reduced anti-apoptotic potential. In contrast, survivin-deltaEx3 lacks exon 3, is localised in the nuclei and preserves anti-apoptotic function to a large extent. Recently, survivin-2B has been applied to peptide vaccine therapy for colorectal cancer patients, although the clinical trial study was in phase I in 2004 [6] .
As described above, survivin might represent a novel critical target in cancer therapy. However, only a few studies concerning survivin in oesophageal squamous cell carcinoma (ESCC) have included a small series, although ESCC remains a major histological feature and generally reveals unfavourable prognosis despite the availability of multimodal therapies in Asia, including Japan [7] [8] [9] [10] [11] [12] [13] [14] . In addition, no studies have examined splice variant expression of survivin in ESCC.
The present study, therefore, investigated the clinical impact of survivin expression in patients with ESCC using immunohistochemical examination of formalin-fixed paraffinembedded tissues, and analysis of splice variant forms using reverse-transcription polymerase chain reaction (RT-PCR).
Materials and methods

Patients and tissue samples
The subjects comprised 71 patients with ESCC (63 men, 8 women; mean age, 63.8 years; range, 43-84 years) were included in the present study. These patients, with or without lymph node metastasis except other organ metastasis, had undergone oesophagectomy and lymphadenectomy without preoperative supplemental therapy at our institute between January 1990 and December 2000. Resected specimens were classified in accordance with the TNM (tumour, node, metastasis) classification system of the International Union Against Cancer (UICC) [15] . In addition, invasion of cancer into lymphatic and blood vessels was assessed microscopically.
Immunohistochemistry
Immunohistochemical staining for survivin was performed using representative paraffin-embedded specimens from the 71 patients included in this study. Sections (4 mm) were cut from resected specimens fixed in 10% buffered formalin and embedded in paraffin. After deparaffinisation and rehydration, tissue sections were autoclaved at 121 8C in citrate buffer (10 mM, pH 6.0) for 10 min for antigen retrieval. Specimens were then incubated with anti-survivin polyclonal antibody (1:20; Alpha Diagnostic International, San Antonio, TX, USA) for 12 h at 4 8C. Immunohistochemical staining, following a standard avidin-biotin-peroxidase complex technique, was performed using the Histofine SAB-PO kit (Nichirei, Tokyo, Japan) and 3,3 0 -diaminobenzidine as the chromogen. Nuclei were counterstained using haematoxylin.
The basal layer of oesophageal epithelium was evaluated as a positive control and a specimen analysed without survivin polyclonal antibody was used as a negative control.
The immunohistochemical status of nuclei and cytoplasm was evaluated by a combination of distribution and colouration in cancer cells. Concerning colouration, cancer cells revealing strong colour were considered positive, whereas an unclear/weak reaction was determined as negative. Specimens staining for survivin were considered as positive case when positive cells could be observed in >50% or >10%, whereas those with negative reactions in >50% or >10% were characterised as negative cases, in evaluations for cytoplasm and nuclei, respectively. Specimens were evaluated by two independent observers who were blinded to clinical information.
Total RNA extraction
For analysis of survivin splice variant expression, freshly frozen tissues were obtained from a recent series of surgically resected ESCC. A section of viable tumour was dissected macroscopically and stored at À80 8C until use. Total RNA were isolated from freshly frozen tissues using an RNeasy Mini Kit (Qiagen, Hilden, Germany) following the protocols outlined by the manufacturer.
RT-PCR for survivin-mRNA expression
Total RNA (1 mg), random primer (GE Healthcare, Little Chalfont, UK), 10 mM dNTP and Super Script II (Invitrogen, Carlsbad, CA, USA) were used for first-strand cDNA synthesis.
Primer sequences and RT-PCR conditions used in this study for the survivin gene were described in our previous report [8] . PCR product (10 ml) was analysed by electrophoresis through a 2% agarose gel (High Strength Analytical Grade Agarose; BioRad, Hercules, CA, USA) containing ethidium bromide and visualised using a Mini-Transilluminator (Funakoshi, Tokyo, Japan). Gene expression status of survivin was determined as overexpression when the PCR product was more amplified in tumour tissue compared with matched normal oesophageal epithelium after visualisation by electrophoresis.
Statistical methods
Correlations between survivin protein or each form of mRNA expression and clinicopathological factors were analysed using the Mann-Whitney U test, Fisher's exact probability test or chi-square test. The Kaplan-Meier method was used to assess prognosis after surgery and a Cox hazard proportional regression model was used for multivariate analysis. Differences were evaluated using the log-rank test. Values of p < 0.05 were considered statistically significant.
Results
Immunohistochemistry
Some cancer cells revealed positive immunohistochemical reactions for survivin in the nuclei and/or cytoplasm (Fig. 1) . Of the 71 cases, cytoplasmic positivity was seen in 22 cases (31%) and nuclear positivity in 10 cases (14%). Cytoplasmic expression of survivin was significantly correlated with histological grade ( p < 0.01) and tumour invasion ( p < 0.01). In contrast, nuclear expression revealed no correlation with clinicopathological factors (Table 1) . Cytoplasmic expression for survivin exhibited significant clinical impact and positive cases revealed unfavourable prognosis compared with negative cases in univariate analysis ( p < 0.05) (Fig. 2) . However, nuclear expression displayed no prognostic impact, although positive cases tended to reveal more favourable prognosis ( p = 0.12) (Fig. 3) . In multivariate analysis including conventional pathological parameters, depth of tumour invasion, nodal status, distant metastasis and cytoplasmic survivin expression, nodal status ( p < 0.05), distant metastasis ( p < 0.001) and survivin expression ( p < 0.05) were identified as independent prognostic parameters (Table 2) .
Splice variant expression by RT-PCR
Survivin mRNA expression could be detected by RT-PCR (Fig. 4) . Of 37 cases, survivin mRNA was seen in 31 cases (84%), survivin-2B mRNA in 26 cases (70%) and survivin-deltaEx3 mRNA in 23 cases (62%). A significant implication was found between survivin-deltaEx3 and histological grade ( p < 0.05). However, no other significant implication was detected between mRNA expression and clinicopathological parameters (Table 3 ).
Discussion
Several studies have been published concerning the implication of the correlation between survivin expression and clinicopathological parameters in ESCC [7] [8] [9] [10] 12, 13, 16] . Of these, four studies examined mRNA expression using RT-PCR and others examined protein expression by immunohistochemical staining.
Kato and Ikeguchi reported that survivin mRNA overexpression compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a control indicated significantly unfavourable prognosis [7, 8, 12] . By contrast Warnecke-Eberz revealed that high survivin mRNA expression ratio of cancer/ normal tissue related with favourable prognosis after surgery [16] .
Concerning the studies using immunohistochemical examinations, three of the four studies reported nuclear survivin expression as a prognostic predictor in ESCC [9, 12, 13] . However, Dabrowski stated that survivin expression could not Fig. 4 . mRNA expression by RT-PCT. Survivin mRNA expression could be detected clearly in almost cases (84%). Splice variant form survivin-2B (70%) and deltaEx3 (62%) were also detected but not clearly compared with surviving mRNA. Table 3 Clinicopathological implication of survivin, survivin-2B or survivin-deltaEx3 mRNA expression. (1) Fisher's exact provability test and (2) chi-square test.
be detected in the nuclei and cytoplasmic expression was not identified as a prognostic parameter in ESCC [10] .
To date, only a single study by Rosato demonstrates any clinical impact of survivin using both RT-PCR and immunohistochemical techniques [12] .
Consensus has thus been lacking concerning the clinical impact of survivin expression in ESCC using either RT-PCR or immunohistochemistry, although discrepancies may have arisen due to differences in controls or antibodies used in semi-quantitative RT-PCR or immunohistochemistry, respectively. Further study was thus required and we examined the clinicopathological impact of survivin expression in ESCC.
Interestingly, we were able to detect preponderantly survivin expression in cytoplasm using immunohistochemical staining in this study. Our results concerning the localisation status of survivin resembled those of Dabrowski, despite using the same antibody as that used by Mega, and we identified a significant prognostic impact [10, 13] . However, nuclear survivin expression did not display any significant prognostic impact, even after resetting cut-off values according to previous reports [9, 13] . Subcellular localisation might be important for survivin to act as a key anti-apoptotic gene. Mahotka demonstrated two novel splice variants of survivin in 1999, with survivin-deltaEx3 conserving the antiapoptotic properties and survivin-2B displaying reduced antiapoptotic potential [4] . Furthermore, >50% of survivin and survivin-2B localised in the cytoplasm; survivin-deltaEx3 was found in the nuclei [17, 18] . Therefore, studying the clinicopathologic impact of survivin to analyse the subcellular localisation is very critical, and cytoplasmic expression should exhibit a prognostic impact, given that survivin has been demonstrated to conserve the most anti-apoptotic potential of three variants, and this finding might support our results in this study. In addition, previous reports suggesting a clinical impact of nuclear expression might reflect expression of the deltaEx3 form.
Our finding that survivin mRNA was mainly amplified by RT-PCR in almost all cases might support the results of immunohistochemical study, although neither splice variant of survivin exhibited a correlation with clinicopathological parameters except between survivin-deltaEx3 and histological grade. In the literature, survivin mRNA has been examined semi-quantitatively and quantitatively [7, 8, 12, 16] . In contrast, we examined survivin and splice variants mRNA only qualitatively and correlated the findings to clinicopathological parameters, with mRNA expression detected in most cases. No studies have investigated the expression of splice variants in ESCC and this is the first study to do so to the best of our knowledge.
In addition, survivin expression has recently been worthy of notice from the perspective of immunotherapy using survivin-2B-derived peptide vaccine [17] . Hirohashi et al. reported that survivin-2B80-88 is capable of binding to human leucocyte antigen (HLA-A24) and cytotoxic T lymphocytes revealed cytotoxicity to HLA-A24-positive survivin-2B-positive cancer cells. In fact, a phase I clinical study using survivin-2B-derived peptide vaccine therapy has been started against advanced or recurrent colorectal cancer [18] . Furthermore, Ichiki demonstrated that 23.8% of lung cancers with both survivin-2B and HLA-A24 expression have been estimated as candidates for vaccine therapy, and that survivin-2B has been detected in squamous cell carcinomas, which are frequently compared to adenocarcinomas of the lung [19] . Squamous cell carcinomas remain the major histological type of the oesophagus in the East and HLA-A24 is known as the dominant population in Asia, including Japan. Given our result of the high frequency of survivin-2B expression (70.3%), ESCC might be a good candidate for immunotherapy using survivin-2B peptide vaccine.
In conclusion, survivin expression appears to represent not only a prognostic predictor, but also a novel target of immunotherapy in ESCC.
